Download PDF
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2020; 12(03): 227-232
DOI: 10.4103/ijmbs.ijmbs_106_20
Conference Highlights

The 80th annual (virtual) conference of the American Diabetes Association: June 12–16, 2020

Mohamed Suliman
1   Imperial College London Diabetes Centre, Al Ain
,
Nagi Mohammed
1   Imperial College London Diabetes Centre, Al Ain
,
Sara Suliman
2   Imperial College London Diabetes Centre, Abu Dhabi
› Author Affiliations
› Further Information
   Permissions and Reprints

A large number of presentations on clinical, basic science, and genetics were discussed at the first virtual American Diabetes Association conference held in June 2020. Studies of relevance to practicing clinicians included the results of the VERTIS-CV study that confirmed the SGLT2 inhibitor ertugliflozin was similar to other drugs in the group in terms of cardiovascular safety, heart failure, and renal benefits. A symposium on heart failure also highlighted the benefits of this group of drugs for treating heart failure both in patients with and without diabetes. The new Food and Drug Administration guidance for new diabetes drugs was presented and created a lively discussion about the pros and cons of these new rules. Another lively debate on whether there is a place for sulfonylureas in the era of the modern diabetes medications reached the conclusion that there is probably still a place for these old and established drugs. On the lipid front, the safety of statins was emphasized in face of negative publicity in the social media, while the recently published REDUCE-IT study showed that tackling low-density lipoprotein cholesterol only may not be enough in the battle against increased cardiovascular risk in diabetes. Looking to the future, a weekly basal insulin may be in sight in a few years' time.

Key-words:

American Diabetes Association - annual conference - virtual

Financial support and sponsorship

Nil.




Publication History

Received: 19 August 2020

Accepted: 04 September 2020

Article published online:
14 July 2022

© 2020. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus 19 in China. N Engl J Med 2020;382:1708-20.
  • 2 Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14:813-21.
  • 3 Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
  • 4 Jensen MH, Kjolby M, Hejlesen O, Jakobsen PE, Vestergaard P. Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality for widely used antihyperglycemic dual and triple therapies for type 2 diabetes management: A cohort study of all Danish users. Diabetes Care 2020;43:1209-18.
  • 5 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
  • 6 ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
  • 7 Edridge CL, Dunkley AJ, Bodicoat DH, Rose TC, Gray LJ, Davies MJ, et al. Prevalence and incidence of hypoglycemia in 532,542 people with type 2 diabetes on oral therapies and insulin: A systematic review and meta-analysis of population-based studies. PLOS One 2015;10:e0126427.
  • 8 Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. CAROLINA Investigators. Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA 2019;321:69-79.
  • 9 Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): A double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5:597-609.
  • 10 Mathieu C, Zinman B, Hemmingson J, Woo V, Colman P, Christiansen E, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: The ADJUNCT ONE treat to target randomized trial. Diabetes Care 2016;39:1702-10.
  • 11 Ahern B, Hirsch I, Pieber T, Mathieu C, Gómez-Peralta F, Hansen TK, et al. efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The ADJUNCT TWO randomized trial. Diabetes Care 2016;39:693-701.
  • 12 Dejgaard F, Frandsen C. Holst J, Madsbad S. Liraglutide for treating type 1 diabetes. Expert Opin Biol Ther 2016;16:579-90.
  • 13 Muso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT1/2 inhibitor sotagliflozin in type 1 diabetes: Meta-analysis of randomised controlled trials. BMJ 2019;365:I1328.
  • 14 Newman C, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events. A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2018;38:e00.
  • 15 Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Association of omega-3 fatty acid supplemental use with cardiovascular risks. Meta-analyses of 10 trials involving 77,917 individuals. JAMA Cardiol 2018;3:225-34.
  • 16 Bhatt D, Steg P, Miller M, Brinton EA, Jacobson TA, Ketchum SB,et al. Cardiovascular risk reduction with icosapentethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med 2019;380:11-22.
  • 17 Knowler W, Barrett-Connor E, Fowler S, Hamman RF, Lachin JM, Walker EA, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
  • 18 McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019;21:665-75.
  • 19 Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487-93.